Thus, new trials could be readily designed to assess the efficacy of these agents in patients with NSCLC with BM harboring CDK12, DDR2, ERBB2, or NTRK1 amplifications or mutations. The gene discussed is CDK12; the disease is non-small cell lung carcinoma.